{"result": {"id": "7ac98d8d-541a-4b01-bfde-19c0473fdaf8", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>高血压患者<|>EVENT<|>Hypertension patients who can benefit from intensive lipid-lowering therapy based on ASCVD risk stratification)\n##\n(\"entity\"<|>糖尿病患者<|>EVENT<|>Diabetes patients requiring LDL-C and non-HDL-C management with statins and other lipid-lowering therapies)\n##\n(\"entity\"<|>缺血性卒中患者<|>EVENT<|>Ischemic stroke patients who benefit from lipid-lowering therapy despite potential hemorrhagic stroke risks)\n##\n(\"entity\"<|>出血性卒中<|>EVENT<|>Hemorrhagic stroke that requires careful risk-benefit assessment when considering lipid-lowering therapy)\n##\n(\"entity\"<|>他汀类药物<|>ORGANIZATION<|>Statins used as primary lipid-lowering therapy for ASCVD risk reduction in various patient groups)\n##\n(\"entity\"<|>胆固醇吸收抑制剂<|>ORGANIZATION<|>Cholesterol absorption inhibitors used as adjunct therapy when statins alone don't achieve LDL-C targets)\n##\n(\"entity\"<|>贝特类药物<|>ORGANIZATION<|>Fibrates used to manage triglyceride levels but require dose adjustment in CKD patients)\n##\n(\"entity\"<|>ω-3脂肪酸<|>ORGANIZATION<|>Omega-3 fatty acids used as adjunct therapy for triglyceride management)\n##\n(\"entity\"<|>山东大学齐鲁医院<|>GEO<|>Qilu Hospital of Shandong University where Zhang Yun is affiliated)\n##\n(\"entity\"<|>山东省立医院<|>GEO<|>Shandong Provincial Hospital where Zhao Jiajun is affiliated)\n##\n(\"entity\"<|>北京大学人民医院<|>GEO<|>Peking University People's Hospital where Hu Dayi is affiliated)\n##\n(\"entity\"<|>北部战区总医院<|>GEO<|>Northern Theater General Hospital where Han Yaling is affiliated)\n##\n(\"relationship\"<|>高血压患者<|>ASCVD<|>Hypertension patients are risk-stratified using ASCVD criteria to determine LDL-C targets<|>7)\n##\n(\"relationship\"<|>糖尿病患者<|>LDL-C<|>Diabetes patients have specific LDL-C and non-HDL-C targets for lipid management<|>8)\n##\n(\"relationship\"<|>缺血性卒中患者<|>出血性卒中<|>Ischemic stroke patients require balance between lipid-lowering benefits and hemorrhagic stroke risks<|>6)\n##\n(\"relationship\"<|>他汀类药物<|>CKD<|>Statins require dose adjustment in CKD patients due to increased myopathy risk<|>7)\n##\n(\"relationship\"<|>胆固醇吸收抑制剂<|>PCSK9 INHIBITOR<|>Both are used as adjunct therapies when statins alone don't achieve LDL-C targets<|>5)\n##\n(\"relationship\"<|>贝特类药物<|>CKD<|>Fibrates require dose adjustment in CKD patients and may increase creatinine levels<|>6)\n##\n(\"relationship\"<|>ω-3脂肪酸<|>IPE<|>Both are used for triglyceride management in high-risk patients<|>5)\n##\n(\"relationship\"<|>张运<|>山东大学齐鲁医院<|>Zhang Yun is affiliated with Qilu Hospital of Shandong University<|>9)\n##\n(\"relationship\"<|>赵家军<|>山东省立医院<|>Zhao Jiajun is affiliated with Shandong Provincial Hospital<|>9)\n##\n(\"relationship\"<|>胡大一<|>北京大学人民医院<|>Hu Dayi is affiliated with Peking University People's Hospital<|>9)\n##\n(\"relationship\"<|>韩雅玲<|>北部战区总医院<|>Han Yaling is affiliated with Northern Theater General Hospital<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165937, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 828, "prompt_tokens": 3832, "total_tokens": 4660, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3776}, "prompt_cache_hit_tokens": 3776, "prompt_cache_miss_tokens": 56}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 群的血脂管理\n5.1    高血压患者\n　　高血压患者能从强化降脂中明显获益。应根据  ASCVD 危险分层确定高血压患者相应的 LDL-C 目标值。 对于高血压合并危险因素归为 ASCVD 中危及以上患者， 应予以积极降胆固醇治疗，LDL-C 至少应 <2.6 mmol/L。\n5.2    糖尿病患者\n　　对于糖尿病患者，推荐同时采用 LDL-C 和非 HDL-C 作为降脂靶点。\n\n　　建议 ASCVD 风险为 高危的糖 尿病患者选择中等 强度他汀类药物作为基础降脂治疗，如果 LDL-C 不 达标，需联用胆固醇吸收抑制剂或 PCSK9 抑制剂［21， 26］。如 果 LDL-C 达 标 后 仍 有 TG 增 高 或 非 HDL-C 不 达标，考虑联用 IPE 或其他 ω-3 脂肪酸或贝特类药 物［17，19-20］。\n5.3    慢性肾脏病（ CKD ）患者\n　　对于轻中度肾功能不全患者，他汀类药物治疗能显 著降低其 ASCVD 风险［28］ ；对于透析依赖的重度肾功 能不全患者，他汀类药物干预研究未显示效果［29-30］。\n　　CKD 患者是他汀类药物引起肌病的高危人群，发 病风险与他汀类药物剂量密切相关，故应避免大剂量应 用。贝特类药物可升高肌酐水平，在中重度 CKD 患者\n\n\n　中与他汀类药物联用时，可能增加肌病风险，联合用药 时应依据肾小球滤过率调整剂量［31-32］。\n5.4    卒中患者\n　　缺血性卒中患者可从降脂治疗中获益。对于缺血性 卒中患者，目前中等剂量他汀类药物增加出血性卒中风 险的证据不充分，降低 LDL-C 的获益远大于有潜在出 血性卒中的风险。存在出血性卒中高风险或有出血性卒 中病史的患者应个体化评估降脂治疗的获益与风险， LDL-C 目标值不宜过低。\n　\n\n　中国血脂管理指南（基层版 2024 年）修订联合专 家委员会\n　　指南修订组织机构：国家心血管病专家委员会，中 华医学会心血管病学分会，中华医学会内分泌学分会， 中华医学会糖尿病学分会，中华医学会检验医学分会， 中国卒中学会\n　　指南修订指导委员会（按姓氏笔画排序）：王成彬  （解放军总医院全军医学检验质量控制中心，中华医学  会检验医学分会主任委员），张运（山东大学齐鲁医院）， 赵家军（山东省立医院，中华医学会内分泌学分会主任 委员），胡大一（北京大学人民医院） ，韩雅玲（北部  战区总医院，中华医学会心血管病学分会主任委\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ASCVD<|>EVENT<|>ASCVD is a cardiovascular disease risk stratification used to determine LDL-C target values for patients with hypertension and diabetes)\n##\n(\"entity\"<|>LDL-C<|>EVENT<|>LDL-C is a cholesterol metric used to assess and manage cardiovascular risk in patients with hypertension, diabetes, and CKD)\n##\n(\"entity\"<|>PCSK9 INHIBITOR<|>ORGANIZATION<|>PCSK9 inhibitors are a class of drugs used to lower LDL-C levels in high-risk patients)\n##\n(\"entity\"<|>IPE<|>ORGANIZATION<|>IPE is a medication used to manage triglyceride levels in patients with high ASCVD risk)\n##\n(\"entity\"<|>CKD<|>EVENT<|>Chronic Kidney Disease (CKD) affects ASCVD risk and influences the choice and dosage of lipid-lowering therapies)\n##\n(\"entity\"<|>TG<|>EVENT<|>Triglycerides (TG) are a lipid parameter monitored in diabetes management alongside LDL-C and non-HDL-C)\n##\n(\"entity\"<|>NON-HDL-C<|>EVENT<|>Non-HDL-C is a secondary lipid target used in diabetes management to assess cardiovascular risk)\n##\n(\"entity\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>ORGANIZATION<|>The committee responsible for revising the Chinese guidelines for lipid management in primary care settings)\n##\n(\"entity\"<|>国家心血管病专家委员会<|>ORGANIZATION<|>National expert committee on cardiovascular diseases involved in guideline revision)\n##\n(\"entity\"<|>中华医学会心血管病学分会<|>ORGANIZATION<|>Chinese Medical Association's branch for cardiovascular diseases, part of the guideline revision team)\n##\n(\"entity\"<|>中华医学会内分泌学分会<|>ORGANIZATION<|>Chinese Medical Association's branch for endocrinology, involved in lipid management guidelines)\n##\n(\"entity\"<|>中华医学会糖尿病学分会<|>ORGANIZATION<|>Chinese Medical Association's branch for diabetes, contributing to lipid management guidelines)\n##\n(\"entity\"<|>中华医学会检验医学分会<|>ORGANIZATION<|>Chinese Medical Association's branch for laboratory medicine, part of the guideline revision)\n##\n(\"entity\"<|>中国卒中学会<|>ORGANIZATION<|>Chinese Stroke Association, involved in the revision of lipid management guidelines)\n##\n(\"entity\"<|>王成彬<|>PERSON<|>Director of the PLA General Hospital's Medical Laboratory Quality Control Center and head of the Chinese Medical Association's Laboratory Medicine Branch)\n##\n(\"entity\"<|>张运<|>PERSON<|>Affiliated with Qilu Hospital of Shandong University, involved in guideline revision)\n##\n(\"entity\"<|>赵家军<|>PERSON<|>Director of Shandong Provincial Hospital and head of the Chinese Medical Association's Endocrinology Branch)\n##\n(\"entity\"<|>胡大一<|>PERSON<|>Affiliated with Peking University People's Hospital, part of the guideline revision committee)\n##\n(\"entity\"<|>韩雅玲<|>PERSON<|>Director of the Northern Theater General Hospital and head of the Chinese Medical Association's Cardiovascular Branch)\n##\n(\"relationship\"<|>ASCVD<|>LDL-C<|>ASCVD risk stratification determines LDL-C target values for patients<|>8)\n##\n(\"relationship\"<|>PCSK9 INHIBITOR<|>LDL-C<|>PCSK9 inhibitors are used to lower LDL-C levels in high-risk patients<|>7)\n##\n(\"relationship\"<|>IPE<|>TG<|>IPE is used to manage elevated triglyceride levels in patients<|>6)\n##\n(\"relationship\"<|>CKD<|>ASCVD<|>CKD patients have modified ASCVD risk and treatment considerations<|>5)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>国家心血管病专家委员会<|>The national cardiovascular committee is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>中华医学会心血管病学分会<|>The cardiovascular branch is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>中华医学会内分泌学分会<|>The endocrinology branch is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>中华医学会糖尿病学分会<|>The diabetes branch is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>中华医学会检验医学分会<|>The laboratory medicine branch is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>中国血脂管理指南（基层版 2024 年）修订联合专家委员会<|>中国卒中学会<|>The stroke association is part of the joint expert committee revising the guidelines<|>6)\n##\n(\"relationship\"<|>王成彬<|>中华医学会检验医学分会<|>Wang Chengbin is the director of the Chinese Medical Association's Laboratory Medicine Branch<|>9)\n##\n(\"relationship\"<|>张运<|>山东大学齐鲁医院<|>Zhang Yun is affiliated with Qilu Hospital of Shandong University<|>8)\n##\n(\"relationship\"<|>赵家军<|>中华医学会内分泌学分会<|>Zhao Jiajun is the director of the Chinese Medical Association's Endocrinology Branch<|>9)\n##\n(\"relationship\"<|>胡大一<|>北京大学人民医院<|>Hu Dayi is affiliated with Peking University People's Hospital<|>8)\n##\n(\"relationship\"<|>韩雅玲<|>中华医学会心血管病学分会<|>Han Yaling is the director of the Chinese Medical Association's Cardiovascular Branch<|>9)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_305115f1cff2b9ef6557dabfe1bd59e8ac0eac893f9bb3287d80448b1356e54c_v2"}